Healthcare Sales & Marketing Network News: PSMA

Searching News Database: PSMA

HSMN NewsFeed - 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 16 Feb 2024
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 3 Nov 2023
Actinium Appoints Lynn Bodarky as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Sep 2023
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 May 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Feb 2022
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
Biopharmaceuticals Diagnostics Oncology FDA

HSMN NewsFeed - 23 Aug 2021
Lightpoint Medical and Telix Pharmaceuticals Announce Strategic Collaboration Agreement
Devices Radiology Oncology

HSMN NewsFeed - 9 Jun 2021
Lightpoint Medical Expands Executive Leadership Team with Appointment of Graeme Smith to CEO
Devices Personnel

HSMN NewsFeed - 10 Jan 2020
Theragnostics Expands Team with Significant Appointments
Biopharmaceuticals Oncology Radiology Personnel

HSMN NewsFeed - 27 Jun 2019
Bracco Imaging Expands Portfolio of Personalized Diagnostics With the Acquisition of Blue Earth Diagnostics
Diagnostics Mergers & Acquisitions

HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2017
Aytu BioScience Announces Appointment of David Green as Chief Financial Officer
Biopharmaceuticals Urology Personnel

HSMN NewsFeed - 26 Oct 2017
Aytu BioScience Provides Quarterly Update on the Natesto(R) U.S. Launch
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 3 Oct 2017
Aytu BioScience Announces International Distribution Agreement for Fiera(R) in Japan
Biopharmaceuticals Urology Distribution

HSMN NewsFeed - 13 Jul 2017
Aytu BioScience Expands MiOXSYS(R) Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe
Diagnostics Urology Distribution

HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2017
First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Dec 2016
Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Jun 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Devices Urology Product Launch

HSMN NewsFeed - 27 Jan 2016
Aytu BioScience Announces Additions to Board of Directors
Biopharmaceuticals Urology Personnel

HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Biopharmaceuticals Urology Regulatory

HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Sep 2014
BIND Therapeutics Appoints Two New Board Members
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Jul 2014
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Jan 2014
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Jan 2014
BIND Therapeutics Announces Departure of Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 19 Feb 2013
Berkley C. Nelson Joins Sharps Compliance as Senior Vice President of Sales
Devices Personnel

HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2010
Vycor Medical Continues to Build Its Sales and Marketing Infrastructure for Its ViewSite(TM) Neurosurgery Retraction Devices
Devices Neurosurgery Personnel

HSMN NewsFeed - 4 Aug 2009
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Biopharmaceuticals

HSMN NewsFeed - 3 Jul 2008
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals

HSMN NewsFeed - 24 Apr 2008
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Mar 2008
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2007
Cytogen Announces Executive Management Changes
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory

HSMN NewsFeed - 11 Jun 2007
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2007
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 May 2007
Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 30 Mar 2007
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 8 Feb 2007
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
Biopharmaceuticals Radiology Oncology

HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Oct 2006
Cytogen Appoints Kevin Bratton New Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Oct 2006
Cytogen Acquires North American Marketing Rights to CAPHOSOL(R) for Treatment of Both Oral Mucositis and Dry Mouth
Biopharmaceuticals Licensing

HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals

HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy

HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jul 2006
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Biopharmaceuticals FDA

HSMN NewsFeed - 22 May 2006
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
Diagnostics Urology Oncology

HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology

HSMN NewsFeed - 8 May 2006
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA

Return to NewsFeed

Additional items found! 87

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 87 additional stories matching:
PSMA
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.